Conclusions : According to the published literature , the clinimetric properties of HAM-D6 are superior to those of both the HAM-D17 and MADRS .
Background : In a study aim ed at identifying the items carrying information regarding the global severity of depression , the 6-item Hamilton Depression Rating Scale ( HAM-D6 ) was derived from the original 17-item version of the scale ( HAM-D17 ) .
Since then , the HAM-D6 has been used in a wide range of clinical studies .
We now provide a systematic review of the clinimetric properties of HAM-D6 in comparison with those of HAM-D17 and the Montgomery Asberg Depression Rating Scale ( MADRS ) .
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
OBJECTIVE This study investigated the efficacy , safety , and tolerability of the selegiline transdermal system ( STS ) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder ( MDD ) . METHOD Patients meeting DSM-IV criteria for MDD ( N = 265 ) were r and omly assigned to blinded treatment with STS or a matching placebo patch for 8 weeks . Patients failing to meet or maintain protocol -defined therapeutic response criteria at predetermined time points had their STS ( or placebo ) dose increased . Assessment s were conducted at weeks 1 , 2 , 3 , 5 , 6 , and 8 . Patients were not required to follow a tyramine-restricted diet . The study ran from September 2001 through August 2002 . RESULTS Selegiline transdermal system treatment result ed in significantly greater improvement ( p < or = .05 ) compared with placebo treatment on the 3 depression rating scales : the 28-item Hamilton Rating Scale for Depression ( HAM-D28 ) ( primary outcome measure ) , the Montgomery-Asberg Depression Rating Scale , and the Inventory for Depressive Symptomatology-Self Rated . The treatment effect measured by the HAM-D28 was modest , primarily due to insomnia side effects . The antidepressant efficacy of STS was substantiated further by the significantly greater improvement in core depression symptoms ( HAM-D Bech-6 subscale ) . The side effects of highest incidence were application site reactions and insomnia . There were no safety concerns based on routine clinical laboratory and electrocardiogram monitoring , and there were no occurrences of hypertensive crisis . CONCLUSION Results of this double-blind , placebo-controlled , dose titration trial provide evidence of short-term efficacy , safety , and tolerability of STS in the dose range of 6 mg/24 hours to 12 mg/24 hours for treatment of MDD . Selegiline transdermal system has an improved margin of safety compared with oral monoamine oxidase inhibitors and represents a useful addition to the existing array of antidepressants
Conclusions : According to the published literature , the clinimetric properties of HAM-D6 are superior to those of both the HAM-D17 and MADRS .
Background : In a study aim ed at identifying the items carrying information regarding the global severity of depression , the 6-item Hamilton Depression Rating Scale ( HAM-D6 ) was derived from the original 17-item version of the scale ( HAM-D17 ) .
Since then , the HAM-D6 has been used in a wide range of clinical studies .
We now provide a systematic review of the clinimetric properties of HAM-D6 in comparison with those of HAM-D17 and the Montgomery Asberg Depression Rating Scale ( MADRS ) .